Hutch News

New prostate cancer cell lines shed light on CRPC

New prostate cancer cell lines shed light on CRPC

From the Haffner Lab, Human Biology Division
Science SpotlightSeptember 20, 2021
Intermittent hormone therapy for prostate cancer inferior to continuous therapy

Intermittent hormone therapy for prostate cancer inferior to continuous therapy

Cathy Tangen contributes to international study, finding on again-off again prostate cancer treatment has quality of life benefits, but continuous therapy improves overall survival
Hutch NewsJune 04, 2012
Postmenopausal estrogen use brings both benefits, risks

Postmenopausal estrogen use brings both benefits, risks

Longer-term Women’s Health Initiative follow-up of estrogen therapy users finds reduced risk of breast cancer, decreased heart disease in younger women
Hutch NewsApril 11, 2011
Even short-term combined hormone therapy use presents risks

Even short-term combined hormone therapy use presents risks

Study finds hormone therapy appears to increase frequency of abnormal mammograms, breast biopsies
Hutch NewsFebruary 25, 2008
Combined hormone therapy increases risk of lobular breast cancer fourfold after just three years of use

Combined hormone therapy increases risk of lobular breast cancer fourfold after just three years of use

Center leads first study designed to evaluate the association between combined HRT use and the risk of lobular breast cancers
Hutch NewsJanuary 07, 2008